9PT Analyst Ratings
Hold
0 Buy
4 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9PT Stock 12 Month Forecast
Average Price Target
€2.16
▲(132.20% Upside)
| Highest Price Target€2.59 | Average Price Target€2.16 | Lowest Price Target€1.73 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
―
Sell
―
Reiterated
08/17/26
Canaccord Genuity
€2.59
Hold
178.64%
Upside
Reiterated
08/13/26
Needham
―
Hold
―
Reiterated
08/12/26
RBC Capital
€1.73
Hold
85.76%
Upside
Reiterated
08/11/26
Piper Sandler
€2.59
Buy
178.64%
Upside
Reiterated
05/12/26
Citi
―
Sell
―
Downgraded
10/10/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
―
Sell
―
Reiterated
08/17/26
Canaccord Genuity
€2.59
Hold
178.64%
Upside
Reiterated
08/13/26
Needham
―
Hold
―
Reiterated
08/12/26
RBC Capital
€1.73
Hold
85.76%
Upside
Reiterated
08/11/26
Piper Sandler
€2.59
Buy
178.64%
Upside
Reiterated
05/12/26
Citi
―
Sell
―
Downgraded
10/10/25
Best Analysts Covering Pliant Therapeutics
3 Months
Success Rate
6/13 ratings generated profit
Average Return
-6.18%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -6.18% per trade.
1 Year
Success Rate
1/13 ratings generated profit
Average Return
-46.54%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -46.54% per trade.
2 Years
Success Rate
0/13 ratings generated profit
Average Return
-61.94%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -61.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9PT Analyst Recommendation Trends
Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
3
1
1
0
Buy
0
0
0
0
0
Hold
4
7
4
4
4
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
6
10
5
5
5
Each month's total comprises the sum of three months' worth of ratings.
9PT Financial Forecast
9PT Stock Forecast FAQ
What is DE:9PT’s average 12-month price target, according to analysts?
Based on analyst ratings, Pliant Therapeutics’s 12-month average price target is 2.16.
What is DE:9PT’s upside potential, based on the analysts’ average price target?
Pliant Therapeutics has 132.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Pliant Therapeutics a Buy, Sell or Hold?
Pliant Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 4 hold ratings and 1 sell ratings.
What is Pliant Therapeutics’s share price target?
The average share price target for Pliant Therapeutics is 2.16. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €2.59 ,and the lowest forecast is €1.73. The average share price target represents 132.20% Increase from the current price of €0.93.
The highest analyst share price target is €2.59 ,and the lowest forecast is €1.73. The average share price target represents 132.20% Increase from the current price of €0.93.
What do analysts say about Pliant Therapeutics?
Pliant Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of Pliant Therapeutics?
To buy shares of DE:9PT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.